Alternatively, approaches for inhibiting Bcl‐xL or Mcl‐1 while avoiding thrombocytopenia or cardiac toxicity include the use of proteolysis‐targeting chimeras (PROTAC) that cause degradation of their target in a tissue‐specific manner [51, 52] or antibody‐drug conjugates (ADC) that selectively deliver the inhibitor to the tumor cells [53]. This evidence concerns the gene BCL2L1 and neoplasm.